一分钟看懂
这是一项关于前列腺癌的III 期研究，登记的药物或干预包括Opevesostat；Abiraterone acetate；Enzalutamide；Hydrocortisone；Fludrocortisone acetate；Prednisone；Dexamethasone，当前状态为招募中。登记地点显示中国合肥、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Opevesostat；Abiraterone acetate；Enzalutamide；Hydrocortisone；Fludrocortisone acetate；Prednisone；Dexamethasone · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408) · 合肥
- Peking University First Hospital-Urology ( Site 0390) · 北京
- Beijing Friendship Hospital Affiliate of Capital University ( Site 0396) · 北京
- Beijing Cancer hospital-Urinary Surgery ( Site 0395) · 北京
- The First Affiliated Hospital of Chongqing Medical University ( Site 0427) · 重庆
- Chongqing University Cancer Hospital ( Site 0416) · 重庆
- Southwest Hospital of Third Military Medical University ( Site 0420) · 重庆
- Chongqing Three Gorges Central Hospital's ( Site 0426) · 重庆
- The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0414) · 福州
- The First Affiliated hospital of Xiamen University-Urology ( Site 0415) · 厦门
- The First Affiliated Hospital of Guangzhou Medical University ( Site 0412) · 广州
- Sun Yat-sen University Cancer Center-Internal medicine ( Site 0413) · 广州
- Tongji Hospital Tongji Medical,Science & Technology ( Site 0407) · 武汉
- Hubei Cancer Hospital-Urinary surgery ( Site 0406) · 武汉
- Hunan Cancer Hospital ( Site 0405) · 长沙
- First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0436) · Huaian
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 0377) · 南京
- Affiliated hospital of Jiangnan university ( Site 0434) · 无锡
- Jiangxi Cancer Hospital ( Site 0386) · 南昌
- The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 0394) · 西安
- The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 0393) · 西安
- Yantai Yuhuangding Hospital ( Site 0397) · 烟台
- Fudan University Shanghai Cancer Center-Urology department ( Site 0376) · 上海
- Zhongshan Hospital Fudan University ( Site 0430) · 上海
- Huadong Hospital Affiliated to Fudan University-Urology ( Site 0388) · 上海
- The Third People's Hospital of Chengdu (CDTPH) ( Site 0428) · 成都
- West China Hospital, Sichuan University-Urology Surgery ( Site 0417) · 成都
- Nanchong Central Hospital-urology ( Site 0422) · 南充
- Suining Central Hospital ( Site 0437) · Suining
- Tianjin Medical University Cancer Institute & Hospital ( Site 0392) · 天津
- The Second Hospital of Tianjin Medical University ( Site 0391) · 天津
- Xinjiang Medical University Cancer Hospital - Urumqi-Urology ( Site 0419) · 乌鲁木齐
- The Second Affiliated Hospital Of Kunming Medical University ( Site 0429) · 昆明
- Yunnan Province Cancer Hospital ( Site 0418) · 昆明
- Zhejiang Provincial People's Hospital-Urology ( Site 0378) · 杭州
- Zhejiang Cancer Hospital ( Site 0435) · 杭州
- The First Hospital of Jiaxing-urology ( Site 0380) · 嘉兴
- The First Affiliated Hospital of Ningbo University ( Site 0383) · 宁波
- The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0379) · 温州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology.
- * Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening
- * Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI).
- * Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA)
- * Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment
- * Has ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<1.7 nM)
- * Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated
- * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06136624；登记信息更新于 2026-10-06；本站同步于 2026-10-08，中国中心当前名额未经人工确认。